HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Yoshiki Sawa Shigeaki Ohtake Toshiki Takahashi Goro Matsumiya Hikaru Matsuda Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Funatsu, T. Articles by Matsuda, H. Search for Related Content PubMed PubMed Citation Articles by Funatsu, T. Articles by Matsuda, H. Related Collections Coronary disease Molecular biology

J Thorac Cardiovasc Surg 2002;124:1099-1105
© 2002 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology (CSP)

Therapeutic angiogenesis in the ischemic canine heart induced by myocardial injection of naked complementary DNA plasmid encoding hepatocyte growth factor

From the Division of Cardiovascular Surgery,^a Department of Surgery E1, and the Division of Biochemistry,^b Department of Oncology, Biomedical Research Center B7, Osaka University Graduate School of Medicine, and the Department of Pathology,^c School of Allied Health Science, Faculty of Medicine, Osaka University, Osaka, Japan.

Received for publication Sept 10, 2001. Revisions requested Oct 10, 2001; revisions received Jan 22, 2002. Accepted for publication Feb 5, 2002. Address for reprints: Yoshiki Sawa, MD, Division of Cardiovascular Surgery, Department of Surgery, Osaka University Graduate School of Medicine E1, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan (E-mail: sawa{at}surg1.med.osaka-u.ac.jp).

Objective: We investigated the efficacy of directly injecting a plasmid with complementary DNA encoding human hepatocyte growth factor into ischemic canine myocardium to induce angiogenesis.
Methods: Four weeks after ligation of the left anterior descending coronary artery, 125 µg of a complementary DNA plasmid encoding the gene for either hepatocyte growth factor (n = 8) or LacZ (transfection control group, n = 8) was injected directly into the myocardium at the border between the normal tissue and the infarction. Eight other dogs were used as a sham control group. Regional thickening fraction, which indicated contractile function, and blood flow in the normal (circumflex branch territory) and ischemic areas were evaluated under dobutamine administration just before and 4 weeks after transfection. The animals were killed, and capillary numbers in both areas were assessed. These data in the ischemic area were evaluated as the percentage of those in the normal.
Results: The number of myocardial capillaries in the ischemic area was successfully increased to approximately 140% of usual in the hepatocyte growth factor group, whereas no change was observed in the other groups (P = .0017 by analysis of variance). Furthermore, regional thickening fraction and blood flow in the ischemic area, which had deteriorated after coronary ligation, showed significant improvement in the hepatocyte growth factor group relative to the other groups (thickening fraction P < .0001 by analysis of variance, blood flow P = .0005 by analysis of variance).
Conclusions: These results support the efficacy of the direct injection of plasmid complementary DNA encoding human hepatocyte growth factor to induce therapeutic angiogenesis in the ischemic myocardium.

This article has been cited by other articles:

				M. Saeed, A. Martin, P. Ursell, L. Do, M. Bucknor, C. B. Higgins, and D. Saloner MR Assessment of Myocardial Perfusion, Viability, and Function after Intramyocardial Transfer of VM202, a New Plasmid Human Hepatocyte Growth Factor in Ischemic Swine Myocardium Radiology, October 1, 2008; 249(1): 107 - 118. [Abstract] [Full Text] [PDF]

				L. Cai, B. H. Johnstone, T. G. Cook, Z. Liang, D. Traktuev, K. Cornetta, D. A. Ingram, E. D. Rosen, and K. L. March Suppression of Hepatocyte Growth Factor Production Impairs the Ability of Adipose-Derived Stem Cells to Promote Ischemic Tissue Revascularization Stem Cells, December 1, 2007; 25(12): 3234 - 3243. [Abstract] [Full Text] [PDF]

				H. Kondoh, Y. Sawa, N. Fukushima, G. Matsumiya, S. Miyagawa, S. Kitagawa-Sakakida, Y. Imanishi, N. Kawaguchi, N. Matsuura, and H. Matsuda Combined Strategy Using Myoblasts and Hepatocyte Growth Factor in Dilated Cardiomyopathic Hamsters Ann. Thorac. Surg., July 1, 2007; 84(1): 134 - 141. [Abstract] [Full Text] [PDF]

				Y. Shirakawa, Y. Sawa, Y. Takewa, E. Tatsumi, Y. Kaneda, Y. Taenaka, and H. Matsuda Gene transfection with human hepatocyte growth factor complementary DNA plasmids attenuates cardiac remodeling after acute myocardial infarction in goat hearts implanted with ventricular assist devices J. Thorac. Cardiovasc. Surg., September 1, 2005; 130(3): 624 - 632. [Abstract] [Full Text] [PDF]

				M. Ono, Y. Sawa, Y. Miyamoto, N. Fukushima, H. Ichikawa, T. Ishizaka, Y. Kaneda, and H. Matsuda The effect of gene transfer with hepatocyte growth factor for pulmonary vascular hypoplasia in neonatal porcine model J. Thorac. Cardiovasc. Surg., April 1, 2005; 129(4): 740 - 745. [Abstract] [Full Text] [PDF]

				M. Ono, Y. Sawa, S. Mizuno, N. Fukushima, H. Ichikawa, K. Bessho, T. Nakamura, and H. Matsuda Hepatocyte Growth Factor Suppresses Vascular Medial Hyperplasia and Matrix Accumulation in Advanced Pulmonary Hypertension of Rats Circulation, November 2, 2004; 110(18): 2896 - 2902. [Abstract] [Full Text] [PDF]

				J. C. Chachques, F. Duarte, B. Cattadori, A. Shafy, N. Lila, G. Chatellier, J.-N. Fabiani, and A. F. Carpentier Angiogenic growth factors and/or cellular therapy for myocardial regeneration: A comparative study J. Thorac. Cardiovasc. Surg., August 1, 2004; 128(2): 245 - 253. [Abstract] [Full Text] [PDF]